MA38279B1 - Therapeutically active pyrazolo-pyrimidine derivatives - Google Patents

Therapeutically active pyrazolo-pyrimidine derivatives

Info

Publication number
MA38279B1
MA38279B1 MA38279A MA38279A MA38279B1 MA 38279 B1 MA38279 B1 MA 38279B1 MA 38279 A MA38279 A MA 38279A MA 38279 A MA38279 A MA 38279A MA 38279 B1 MA38279 B1 MA 38279B1
Authority
MA
Morocco
Prior art keywords
pyrimidine derivatives
therapeutically active
pyrazolo
active pyrazolo
spirocyclic
Prior art date
Application number
MA38279A
Other languages
French (fr)
Other versions
MA38279A1 (en
Inventor
Daniel James Ford
Richard Jeremy Franklin
Anant Ramrao Ghawalkar
Helen Tracey Horsley
Qiuya Huang
James Thomas Reuberson
Bart Vanderhoydonck
Original Assignee
Ucb Biopharma Sprl
Katholieke Universiteit Leuven K U Leuven R&D
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ucb Biopharma Sprl, Katholieke Universiteit Leuven K U Leuven R&D filed Critical Ucb Biopharma Sprl
Priority claimed from PCT/EP2013/077846 external-priority patent/WO2014096423A1/en
Publication of MA38279A1 publication Critical patent/MA38279A1/en
Publication of MA38279B1 publication Critical patent/MA38279B1/en

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Cette invention concerne une série de dérivés de pyrazolo[3,4-d]pyrimidine qui sont substitués à la position 4 par un fragment monocyclique, bicyclique ponté ou spirocyclique de type diaza, qui sont bénéfiques pour traiter et/ou prévenir diverses maladies humaines, comprenant les troubles inflammatoires, autoimmuns et oncologiques ; les maladies virales et le paludisme ; et le rejet de greffes d'organes et de cellules.This invention relates to a series of pyrazolo [3,4-d] pyrimidine derivatives which are substituted at the 4-position by a monocyclic, bridged bicyclic or spirocyclic diaza moiety, which are beneficial for treating and / or preventing various human diseases, including inflammatory, autoimmune and oncological disorders; viral diseases and malaria; and rejection of organ and cell transplants.

MA38279A 2012-12-20 2013-12-20 Therapeutically active pyrazolo-pyrimidine derivatives MA38279B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1223021.5A GB201223021D0 (en) 2012-12-20 2012-12-20 Therapeutic agents
PCT/EP2013/077846 WO2014096423A1 (en) 2012-12-20 2013-12-20 Therapeutically active pyrazolo-pyrimidine derivatives

Publications (2)

Publication Number Publication Date
MA38279A1 MA38279A1 (en) 2018-02-28
MA38279B1 true MA38279B1 (en) 2018-10-31

Family

ID=47682284

Family Applications (1)

Application Number Title Priority Date Filing Date
MA38279A MA38279B1 (en) 2012-12-20 2013-12-20 Therapeutically active pyrazolo-pyrimidine derivatives

Country Status (4)

Country Link
EC (1) ECSP15031293A (en)
GB (1) GB201223021D0 (en)
GT (1) GT201500169A (en)
MA (1) MA38279B1 (en)

Also Published As

Publication number Publication date
GT201500169A (en) 2019-08-30
GB201223021D0 (en) 2013-02-06
MA38279A1 (en) 2018-02-28
ECSP15031293A (en) 2018-07-31

Similar Documents

Publication Publication Date Title
EA201890827A1 (en) CONDENSED DERIVATIVES OF PYRAZOL AS KINASE INHIBITORS
EA201500654A1 (en) THERAPEUTICALLY ACTIVE DERIVATIVES OF PYRAZOLOPYRIMIDINE
CY1121512T1 (en) METHODS AND INTERMEDIATIONS FOR THE PREPARATION OF JAK SUSPENDER
MA40770B1 (en) FUSED PENTACYCLIC IMIDAZOLE DERIVATIVES
EA201100524A1 (en) AZAINDAZOLES AS ANTAGONISTS OF CCR1 RECEPTOR
EA201790228A1 (en) COMPOSITIONS AND METHODS OF OBTAINING PYRIMIDINE AND PYRIDINE COMPOUNDS WITH BTK INHIBITING ACTIVITY
BR112015009942A2 (en) tricyclic fused thiophene derivatives as jak inhibitors
EA201492176A1 (en) SELECTIVE PI3K DELTA INHIBITORS
EA201270480A1 (en) NEW CONNECTIONS
MA52856B1 (en) Heteroaryl or fused aryl bicyclic compounds and their use as irak4 inhibitors
BR112016011484A2 (en) IMIDAZOPYRIMIDINE DERIVATIVES AS MODULATORS OF TNF ACTIVITY
MX2011012353A (en) N-(HETERO)ARYL-PYRROLIDINE DERIVATIVES OF PYRAZOL-4-YL-PYRROLO[2, 3-d]PYRIMIDINES AND PYRROL-3-YL-PYRROLO[2,3-d]PYRIMIDINES AS JANUS KINASE INHIBITORS.
EA201492082A1 (en) CRYSTAL FORMS OF BLUTON TYROSINKINASE INHIBITOR
NO20075560L (en) Purine and imidazopyridine derivatives for immunosuppression
EA201690502A1 (en) SUBSTITUTED PYRIMIDINE INHIBITORS BMI-1
UA111854C2 (en) METHODS AND INTERMEDIATE COMPOUNDS FOR JAK INHIBITORS
EA201990523A1 (en) NEW SELECTIVE JAK1 INHIBITORS AND THEIR APPLICATION
MA37946A1 (en) Treatment of rheumatoid arthritis
CY1119063T1 (en) SUBSTITUTED BICYCLE DYYDROPYRIMIDINONS AND THEIR USE AS SUSPENSIONS OF BACKGROUND ADJUSTMENT
CA2903737C (en) Benzoimidazol-2-yl pyrimidine modulators of the histamine h4 receptor
EA201891897A1 (en) 1,5-DIGIDRO-4H-PYRAZOLO [3,4-d] PYRIMIDIN-4-ONE and 1,5-DIHYDRO-4H-PYRAZOLO [4,3-c] PYRIDIN-4-ONE AS PDE1 INHIBITORS
IN2015DN03751A (en)
TR201901338T4 (en) Pyrazolo-Pyridine Derivatives as Kinase Inhibitors
EA201891710A1 (en) THERAPEUTIC CONNECTIONS
EA201792687A1 (en) Condensed tricyclic imidazopyrazines as modulators of TNF activity